Aripiprazol en el autismo: seguridad y tolerancia
- M Vidal Formoso 1
- F Montañés Rada 2
- 1 Servicios de Salud Mental Distrito de Arganda del Rey. Madrid
- 2 Hospital Universitario Fundación Alcorcón. Madrid
ISSN: 2660-7271, 1130-9512
Any de publicació: 2012
Volum: 29
Número: 1
Pàgines: 25-33
Tipus: Article
Altres publicacions en: Revista de Psiquiatría Infanto-Juvenil
Resum
The aim of this study is to do a review on the efficacy and security of aripiprazole in the treatment of symptoms of irritability associated with autistic disorder. Improve-ments in other symptoms included on the Aberrant Beha-vior Checklist (ABC) are revised as well.In order to do this we have reviewed three studies. The first two are 8-week, randomized, double-blind, multi-center trials to evaluate the efficacy of both aripiprazole fixed doses (5 mg/d, 10mg/d, 15mg/d) and flexible doses (2-15mg/d) versus a placebo. The third study was a post hoc analysis of the two former, and it evaluated the effect of aripiprazol on the 58 items the ABC scale. The results were significant with aripiprazole versus a placebo on the following ABC scale items and with all aripiprazole do-ses used: mood changes quickly, cries/screams, stamps feet, repetitive movement, boisterous, constantly runs or jumps, and tends to be excessively active. Furthermore with the 15mg/d dose significant results were obtained for a greater number of items.